Home / Stocks / Actavis plc (ACT). Analysis and outlook

Actavis plc (ACT). Analysis and outlook

Actavis plc, an integrated pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. It offers generic, branded, branded generic, biosimilar, over-the-counter, biologic, and specialty pharmaceutical products in various formulations, including modified release, solid oral dosage, semi-solids, liquids, gels, transdermal products, and injectables; and develops and out-licenses generic pharmaceutical products to customers through its third-party business.

ACT Technical analysis
ACT is trading in the range of $144.00 – $166.00 in the past 30 days. The stock has been showing support at $154.00 and resistance in the $165.00 range. The stock is trading above the 50-Day Moving Average and above the 200-Day Moving Average. The RSI(14) is 63.51. Our indicators give a bullish view on ACT.